登录 | 注册    关注公众号  
微信公众号
搜索
 > 【CD46】

CD46信息

英文名称:Membrane cofactor protein
中文名称:膜辅因子蛋白
靶点别称:TLX,MCP,CD46,CD46 Molecule,Membrane Cofactor Protein (CD46, Trophoblast-Lymphocyte Cross-Reactive Antigen),Antigen Identified By Monoclonal Antibody TRA-2-10,CD46 Molecule, Complement Regulatory Protein,CD46 Antigen, Complement Regulatory Protein,Trophoblast Leukocyte Common Antigen,MIC10,Trophoblast-Lymphocyte Cross-Reactive Antigen,Complement Membrane Cofactor Protein,Trophoblast Leucocyte Common Antigen,Measles Virus Receptor,CD46 Antigen,TRA2.10,AHUS2,Membrane cofactor protein,MGC26544
上市药物数量:0
临床药物数量:3
最高研发阶段:临床二期

CD46产品列表

产品库
物种
属性
货号 物种 产品描述 蛋白结构 纯度 活性
CD6-H5226
Human
Human CD46 Protein, His Tag (MALS verified)
CD6-H5254
Human
Human CD46 Protein, Fc Tag (MALS verified)
ACRO质量管理体系
 
评论(1)
CD6-H5226|Human CD46 Protein, His Tag (MALS verified)
  1. 158XXXXXXX7
  2. 0人赞
  3. 本次购买了Acro的CD6-H5226人源性蛋白,蛋白到货速度非常快,用于抗原抗体特意识别的实验,实验效果很好,服务也很到位。
  4. 2024-08-19
 

CD46分子别名

CD46,AHUS2,MCP,MIC10,TLX,TRA2.10

CD46分子背景

Complement regulatory protein CD46 is also known as membrane Cofactor Protein (MCP), is a type I membrane protein and is a regulatory part of the complement system. CD46 is expressed by all cells except erythrocytes. MCP acts as a cofactor for complement factor I, a serine protease which protects autologous cells against complement-mediated injury by cleaving C3b and C4b deposited on host tissue, and also acts as a costimulatory factor for T-cells which induces the differentiation of CD4+ into T-regulatory 1 cells. In T-cells by binding to CD46, A number of viral and bacterial pathogens seem to exploit this property and directly induce an immunosuppressive phenotype. Defects in CD46 are a cause of susceptibility to hemolytic uremic syndrome atypical type 2 (AHUS2).

CD46临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
FOR-46 FOR-46; FG-3246 临床二期 圣迭戈加利福尼亚大学, Fortis Therapeutics Inc 去势抵抗性前列腺肿瘤, 多发性骨髓瘤, 前列腺癌 详情
Enadenotucirev ColoAd-1; Oncolytic Ad11/Ad3 临床一期 Akamis Bio Ltd 卵巢癌, 直肠癌, 头颈部鳞状细胞癌, 结肠癌, 腺性和上皮性肿瘤, 膀胱癌, 结直肠癌, 非小细胞肺癌 详情
YS-5 YS-5 临床一期 Fortis Therapeutics Inc, 美国国防部 去势抵抗性前列腺肿瘤, 前列腺癌 详情

消息提示

请输入您的联系方式,再点击提交!

确定